TR200403328T2 - Kilo alımını tedavi ve/veya önleme metotları. - Google Patents

Kilo alımını tedavi ve/veya önleme metotları.

Info

Publication number
TR200403328T2
TR200403328T2 TR2004/03328T TR200403328T TR200403328T2 TR 200403328 T2 TR200403328 T2 TR 200403328T2 TR 2004/03328 T TR2004/03328 T TR 2004/03328T TR 200403328 T TR200403328 T TR 200403328T TR 200403328 T2 TR200403328 T2 TR 200403328T2
Authority
TR
Turkey
Prior art keywords
prevention
methods
treatment
weight gain
dehydroepiandrosterone
Prior art date
Application number
TR2004/03328T
Other languages
English (en)
Inventor
Richard Denis
Deshaies Yves
Labrie Fernand
Martel Celine
Original Assignee
Endorecherche, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche, Inc. filed Critical Endorecherche, Inc.
Publication of TR200403328T2 publication Critical patent/TR200403328T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Insanlar da dahil olmak üzere hassas sicak kanli hayvanlarda asiri sismanlik, karin yagi ve ensülin direncinin tibbi tedavisi ve/veya önlenmesi için yeni metotlar selektif östrojen reseptör modülatörlerinin (SERM'ler) uygulanmasini gerektirir. Dehidroepiandrosteron, dehidroepiandrosteron sülfat, androst-5-en-3b,17b-diol ve önceki öncülerin ya da östrojenin herhangi birine in vivo olarak çevrilmis bilesiklerden olusan gruptan seçilmis bir cinsiyet steroid öncüsü ya da östrojenin bir miktari ile bir SERM'in bir kombinasyonu da ayni zamanda açiklanmaktadir.
TR2004/03328T 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları. TR200403328T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06

Publications (1)

Publication Number Publication Date
TR200403328T2 true TR200403328T2 (tr) 2005-03-21

Family

ID=22499734

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/02284T TR200502284T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları
TR2004/03328T TR200403328T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2005/02284T TR200502284T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları

Country Status (25)

Country Link
US (2) US6710059B1 (tr)
EP (1) EP1196163B1 (tr)
JP (1) JP4790178B2 (tr)
KR (1) KR101141763B1 (tr)
CN (1) CN1390126B (tr)
AR (1) AR034091A1 (tr)
AT (1) ATE447947T1 (tr)
AU (3) AU5957500A (tr)
BR (1) BR0012354A (tr)
CA (1) CA2376158C (tr)
DE (1) DE60043305D1 (tr)
DK (1) DK1196163T3 (tr)
HK (1) HK1046240B (tr)
HU (1) HU230543B1 (tr)
IL (2) IL147485A0 (tr)
MX (1) MX270786B (tr)
MY (1) MY134574A (tr)
NO (1) NO329614B1 (tr)
NZ (1) NZ516453A (tr)
PL (1) PL208972B1 (tr)
RU (3) RU2327461C2 (tr)
TR (2) TR200502284T2 (tr)
TW (1) TWI359015B (tr)
WO (1) WO2001001969A2 (tr)
ZA (1) ZA200200085B (tr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731157A3 (en) * 1998-06-11 2009-07-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
TR200502284T2 (tr) * 1999-07-06 2005-08-22 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
CN1400904A (zh) * 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
JP2005504100A (ja) 2001-09-24 2005-02-10 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
WO2004054573A1 (en) * 2002-12-13 2004-07-01 N.V. Nutricia Method and composition for inhibiting carbohydrate digestion
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
US8835413B2 (en) * 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CN101678388B (zh) * 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
BRPI0810370A2 (pt) * 2007-04-17 2014-10-29 Micell Technologies Inc Stent revestido, e, método para preparar um stent
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
CA2756386C (en) * 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
CA2756307C (en) * 2009-03-23 2017-08-08 Micell Technologies, Inc. Peripheral stents having layers and reinforcement fibers
WO2010120552A2 (en) * 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011007882A1 (ja) * 2009-07-16 2011-01-20 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
AU2014248508B2 (en) 2013-03-12 2018-11-08 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
MX2018007844A (es) * 2015-12-22 2019-01-21 Jiangsu Hengrui Medicine Co Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
US10729650B2 (en) * 2017-01-23 2020-08-04 United States Of America As Represented By The Secretary Of The Air Force Skin punch biopsy and wound-debridgement training model
WO2021247601A1 (en) 2020-06-02 2021-12-09 Model Medicines, Inc. Methods and compositions for treating rna viral infections
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CA2091102C (en) * 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
WO1999002152A1 (en) * 1997-07-10 1999-01-21 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
BR9811946A (pt) * 1997-08-15 2000-08-22 Univ Duke Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
EP1021191B1 (de) * 1997-10-08 2002-06-05 Genesiscosmetics Rights & Licenses Company Limited Straffung und/oder verkleinerung von fettzellen-haltigen körperpartien
ID26890A (id) 1998-05-15 2001-02-15 American Home Prod 2-fenil-1-(4-(2-aminoetoksi) -benzil)-indol dalam kombinasinya dengan estrogen
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1731157A3 (en) 1998-06-11 2009-07-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
TR200502284T2 (tr) * 1999-07-06 2005-08-22 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları

Also Published As

Publication number Publication date
MY134574A (en) 2007-12-31
MX270786B (es) 2009-10-08
HUP0202363A2 (en) 2002-10-28
TWI359015B (en) 2012-03-01
CN1390126A (zh) 2003-01-08
ATE447947T1 (de) 2009-11-15
HU230543B1 (hu) 2016-11-28
NO20020037L (no) 2002-03-04
NZ516453A (en) 2004-04-30
DE60043305D1 (de) 2009-12-24
AR034091A1 (es) 2004-02-04
CN1390126B (zh) 2012-06-13
HUP0202363A3 (en) 2005-02-28
KR101141763B1 (ko) 2012-05-08
AU2009200258B2 (en) 2012-01-12
HK1046240A1 (en) 2003-01-03
AU2009200258A1 (en) 2009-02-26
RU2636498C2 (ru) 2017-11-23
RU2013148518A (ru) 2015-05-10
IL147485A0 (en) 2002-08-14
WO2001001969A3 (en) 2001-08-02
DK1196163T3 (da) 2010-03-29
US8609695B2 (en) 2013-12-17
RU2008101793A (ru) 2009-07-27
TW200803838A (en) 2008-01-16
EP1196163B1 (en) 2009-11-11
WO2001001969A2 (en) 2001-01-11
HK1046240B (en) 2010-09-30
BR0012354A (pt) 2002-04-02
RU2519642C2 (ru) 2014-06-20
ZA200200085B (en) 2003-06-25
AU2005229713A1 (en) 2005-12-01
JP4790178B2 (ja) 2011-10-12
AU5957500A (en) 2001-01-22
RU2327461C2 (ru) 2008-06-27
CA2376158A1 (en) 2001-01-11
JP2003503446A (ja) 2003-01-28
PL208972B1 (pl) 2011-07-29
PL352993A1 (en) 2003-09-22
CA2376158C (en) 2011-03-15
KR20020020776A (ko) 2002-03-15
TR200502284T2 (tr) 2005-08-22
US20040034000A1 (en) 2004-02-19
NO329614B1 (no) 2010-11-22
US6710059B1 (en) 2004-03-23
MXPA02000075A (es) 2003-05-23
NO20020037D0 (no) 2002-01-04
EP1196163A2 (en) 2002-04-17
IL195860A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
TR200403328T2 (tr) Kilo alımını tedavi ve/veya önleme metotları.
TR200103455T2 (tr) Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
Boisselle et al. New therapeutic approach to the hirsute patient
Surampudi et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive
Liptrap et al. Increase in plasma testosterone concentration after injection of adrenocorticotrophin into the boar
Catherino et al. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity
Mortreux et al. Hindlimb suspension in Wistar rats: Sex-based differences in muscle response
ATE363487T1 (de) 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
Nestler et al. Metabolism and actions of dehydroepiandrosterone in humans
Rochefort et al. Cellular and molecular mechanism of action of antiestrogens
Hutchison Hypothalamic mechanisms of sexual behavior with special reference to birds
HUE028948T2 (en) Device for the treatment of obesity
TR200200429T2 (tr) Kilo alımını tedavi ve/veya önleme metodları.
Liu et al. Androgens, obesity, and sleep-disordered breathing in men
Foidart et al. Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17α-spirolactone-derived progestogen
Ohlsson et al. Sex steroids and bone health in men
Shetty et al. Effects of medroxyprogesterone and estradiol on the recovery of spermatogenesis in irradiated rats
Nelson Steroidal oestrogens added to list of known human carcinogens.
Bradlow et al. Immunological properties of dehydroepiandrosterone, its conjugates, and metabolites
Frye Estradiol tends to improve inhibitory avoidance performance in adrenalectomized male rats and reduces pyknotic cells in the dentate gyrus of adrenalectomized male and female rats
Dorfman et al. Assay of subcutaneously administered androgens on the chick's comb
Levy et al. Congenital adrenal hyperplasia: Is there an effect on penile growth?
Phillips et al. Estratest® and Estratest® HS (esterified estrogens and methyltestosterone) therapy: A summary of safety surveillance data, January 1989 to August 2002
Karkun et al. Maintenance of the epididymis in the castrated golden hamster by testosterone and dihydrotestosterone
Verdonck et al. Effect of testosterone replacement after neonatal castration on craniofacial growth in rats